NCT05430217View on ClinicalTrials.gov

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

PHASE3CompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

May 9, 2022

Study Completion Date

May 9, 2022

Conditions
VertigoAutonomic Dysfunction
Interventions
DRUG

Buspirone

1 tablet (15 mg) once per day for 28 days

DRUG

Placebo

1 placebo tablet once per day for 28 days

Trial Locations (8)

152040

"Regional budgetary health care institution Ivanovo Regional Clinical Hospital", Saint Petersburg

191119

"Limited Liability Company Research Center Eco-Security", Saint Petersburg

194156

"Limited Liability Company X7 Clinical Research", Saint Petersburg

196143

"Limited Liability Company Research Center Eco-Safety", Saint Petersburg

197372

"Limited Liability Company MK-Med", Saint Petersburg

197706

"Saint Petersburg State Budgetary Institution of Healthcare City Hospital No. 40 of Kurortny District", Saint Petersburg

198328

"St. Petersburg State Budgetary Health Institution City Polyclinic No. 106", Saint Petersburg

199178

"Limited Liability Company MART", Saint Petersburg

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY